Business
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Sympos...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025\n\n\n\n\n\n\n BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS\n \n ®\n \n )\n \n\n\n\n\n\n Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to identify patients who benefit from treatment with BriaCell’s regimen\n \n\n\n\n\n\n Maturing Phase 2 study data continues to support meaningful clinical benefit of the Bria-IMT regimen with outstanding long-term survival\n \n\n\n\n\n\n No toxicity related discontinuations in Phase 3\n \n\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, presents positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS\n \n ®\n \n ) taking place December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.\n \n\n “We are very excited to see the robust and positive biomarker data, which may enable us to more confidently predict clinical responses in patients treated with the Bria-IMT regimen early in their treatment course,” stated Kelly E. McCann, MD, PhD, breast medical oncologist at UCLA Health Jonsson Comprehensive Cancer Center, and lead investigator at UCLA for the Bria-ABC pivotal Phase 3 study. “These biomarkers could serve as highly valuable tools for clinicians, helping them inform treatment decisions for metastatic breast cancer, a complex disease in which many patients have limited or no remaining treatment options.”\n \n\n “BriaCell’s data shows the promise of the Bria-IMT regimen to address major unmet needs in the treatment of metastatic breast cancer, including in patients with CNS metastasis who have progressed on several lines of therapy – median 6 prior treatments,” stated Chaitali S. Nangia, MD, Partner, Hoag Medical Group and first author of the poster.\n \n\n “Our findings support further evaluation of cytokine and chem...